Cargando…

SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease

Introduction - The combination of sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and glucocorticoid excess can trigger ketone production by reducing insulin secretion/sensitivity and stimulating glucosuria, glucagon production, and lipolysis. In addition, metabolic alkalosis caused by glucoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagalla, Nicole, Weaver, Anne, Qamar, Ali, Gratian, Lauren, Crowley, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552005/
http://dx.doi.org/10.1210/js.2019-SAT-453
_version_ 1783424502279962624
author Sagalla, Nicole
Weaver, Anne
Qamar, Ali
Gratian, Lauren
Crowley, Matthew
author_facet Sagalla, Nicole
Weaver, Anne
Qamar, Ali
Gratian, Lauren
Crowley, Matthew
author_sort Sagalla, Nicole
collection PubMed
description Introduction - The combination of sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and glucocorticoid excess can trigger ketone production by reducing insulin secretion/sensitivity and stimulating glucosuria, glucagon production, and lipolysis. In addition, metabolic alkalosis caused by glucocorticoid excess (via mineralocorticoid receptor activation) may combine with diabetic ketoacidosis (DKA) to create a mixed acid-base disorder, which can potentially obscure SGLT-2i-associated DKA. Case Description - A 45 year-old man with well-controlled type 2 diabetes on an SGLT-2i presented to the Emergency Room with edema, weakness, palpitations, polyuria/polydipsia, hypertension, and hyperglycemia. Exam was significant for a blood pressure of 195/111mmHg, moon facies, supraclavicular fat pad fullness, obese abdomen with violaceous striae, and reduced bilateral hip flexor weakness. He was found to have potassium 2.5mmol/L, glucose 296mg/dL, bicarbonate 28mmol/L, and anion gap 20mmol/L. Venous pH was 7.51, with pCO2 38mmHg. Beta-hydroxybutyrate was >8.0mmol/L (<0.40). Random cortisol was 59.1ug/dL (5-25ug/dL) and ACTH 313pg/mL (15-66pg/mL). 24hr Urine Cortisol was 1567mcg/24hrs (3.5-45mcg/24hrs). Pituitary MRI showed diffuse pituitary enlargement and a 7mm pituitary adenoma. The patient’s DKA was managed with IV fluids and insulin, and potassium was aggressively replaced. He underwent successful trans-sphenoidal pituitary adenoma resection, with positive ACTH staining on pathology. ACTH and cortisol 12 hours postoperatively were 78pg/mL and 15.1ug/dL, respectively, and continued to downtrend. On the second postoperative day, the patient developed severe anxiety, which improved with increased glucocorticoid supplementation. Conclusion - DKA is a rare side effect of SGLT-2i use, and even rarer in the setting of Cushing’s Disease. In this case, the patient’s underlying Cushing’s Disease likely contributed to the development of SGLT-2i-associated DKA and severe hypokalemia, while also obscuring the diagnosis by causing a concurrent metabolic alkalosis that normalized the pH and bicarbonate. The competing physiologic mechanisms at play led to this unusual presentation of SGLT-2i-associated DKA with an alkalotic pH and normal bicarbonate.
format Online
Article
Text
id pubmed-6552005
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65520052019-06-13 SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease Sagalla, Nicole Weaver, Anne Qamar, Ali Gratian, Lauren Crowley, Matthew J Endocr Soc Neuroendocrinology and Pituitary Introduction - The combination of sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and glucocorticoid excess can trigger ketone production by reducing insulin secretion/sensitivity and stimulating glucosuria, glucagon production, and lipolysis. In addition, metabolic alkalosis caused by glucocorticoid excess (via mineralocorticoid receptor activation) may combine with diabetic ketoacidosis (DKA) to create a mixed acid-base disorder, which can potentially obscure SGLT-2i-associated DKA. Case Description - A 45 year-old man with well-controlled type 2 diabetes on an SGLT-2i presented to the Emergency Room with edema, weakness, palpitations, polyuria/polydipsia, hypertension, and hyperglycemia. Exam was significant for a blood pressure of 195/111mmHg, moon facies, supraclavicular fat pad fullness, obese abdomen with violaceous striae, and reduced bilateral hip flexor weakness. He was found to have potassium 2.5mmol/L, glucose 296mg/dL, bicarbonate 28mmol/L, and anion gap 20mmol/L. Venous pH was 7.51, with pCO2 38mmHg. Beta-hydroxybutyrate was >8.0mmol/L (<0.40). Random cortisol was 59.1ug/dL (5-25ug/dL) and ACTH 313pg/mL (15-66pg/mL). 24hr Urine Cortisol was 1567mcg/24hrs (3.5-45mcg/24hrs). Pituitary MRI showed diffuse pituitary enlargement and a 7mm pituitary adenoma. The patient’s DKA was managed with IV fluids and insulin, and potassium was aggressively replaced. He underwent successful trans-sphenoidal pituitary adenoma resection, with positive ACTH staining on pathology. ACTH and cortisol 12 hours postoperatively were 78pg/mL and 15.1ug/dL, respectively, and continued to downtrend. On the second postoperative day, the patient developed severe anxiety, which improved with increased glucocorticoid supplementation. Conclusion - DKA is a rare side effect of SGLT-2i use, and even rarer in the setting of Cushing’s Disease. In this case, the patient’s underlying Cushing’s Disease likely contributed to the development of SGLT-2i-associated DKA and severe hypokalemia, while also obscuring the diagnosis by causing a concurrent metabolic alkalosis that normalized the pH and bicarbonate. The competing physiologic mechanisms at play led to this unusual presentation of SGLT-2i-associated DKA with an alkalotic pH and normal bicarbonate. Endocrine Society 2019-04-30 /pmc/articles/PMC6552005/ http://dx.doi.org/10.1210/js.2019-SAT-453 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Neuroendocrinology and Pituitary
Sagalla, Nicole
Weaver, Anne
Qamar, Ali
Gratian, Lauren
Crowley, Matthew
SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
title SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
title_full SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
title_fullStr SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
title_full_unstemmed SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
title_short SAT-453 Diabetic "Ketoalkalosis" Due to SGLT2 Inhibitor in the Setting of Cushing's Disease
title_sort sat-453 diabetic "ketoalkalosis" due to sglt2 inhibitor in the setting of cushing's disease
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552005/
http://dx.doi.org/10.1210/js.2019-SAT-453
work_keys_str_mv AT sagallanicole sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease
AT weaveranne sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease
AT qamarali sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease
AT gratianlauren sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease
AT crowleymatthew sat453diabeticketoalkalosisduetosglt2inhibitorinthesettingofcushingsdisease